Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Copaxone in RRMS
NCT00203021Phase 4Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 1994
- Primary completion
- Feb 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Number of Participants With Adverse Events at Month 288 and Change From Baseline in Kurtzke Expanded Disability Status Scale Score at Month 288. Started Mar 1994; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00203021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203021.